Sarcomas

Kjersten Dosumu, DNP, MS, AGPCNP-BC, explains why investigators are optimistic about treating uterine leiomyosarcoma with olaparib and temozolomide.

Two patients experienced 18% and 20% reductions in tumor size following treatment with camsirubicin.

Olaparib plus temozolomide was associated with a 27% overall response rate among 22 patients with pretreated uterine leiomyosarcoma.

Phase 2 findings show that adding a tyrosine kinase inhibitor to dual immunotherapy curbed disease progression in patients with metastatic soft tissue sarcoma.

Nirogacestat significantly reduced pain scores for patients with desmoid tumors.

Milademetan, a MDM2 inhibitor, is associated with thrombocytopenia. An intermittent dosing schedule may help mitigate that adverse event.

The antibody-drug conjugate trastuzumab deruxtecan has demonstrated clinical activity among patients with uterine carcinosarcomas, regardless of HER2 expression level.

Combining the doxorubicin analogue camsirubicin with pegfilgrastim yielded encouraging clinical activity in patients with advanced soft tissue sarcoma.

Patients with treatment-naïve advanced gastrointestinal stromal tumors demonstrated promising responses following treatment with the TKI imatinib plus the MEK inhibitor binimetinib.

The use of PARP inhibitor olaparib in conjunction with temozolomide may be an effective treatment for patients with advanced uterine leiomyosarcoma whose tumors harbor a BRCA-like phenotype.

An expert from the Institut Curie discusses the risk-benefit ratio associated with NBTXR3 plus radiotherapy for the treatment of patients with soft tissue sarcoma.

Patient Reported Outcomes Measurement Information System scoring suggested that wound complication was associated with more severe anxiety and decreased physical function in patients receiving radiation therapy for soft tissue sarcoma.

The FDA has granted a fast track designation for annamycin as a treatment for patients with soft tissue sarcoma lung metastases.

The use of next-generation sequencing demonstrated that 34% of patients with sarcoma had potentially actionable mutations.

Findings from an analysis determined that stage 4 gastrointestinal stromal tumors were rare and led to hepatic metastases, although overall survival was up to 51% at 5 years.

The advent of 3D printing has led to an exciting revolution in limb salvage surgery for patients with bone tumors and soft tissue sarcomas, and have resulted in more precise resection and high-fidelity reconstruction, according to R. Lor Randall, MD, FACS.

The clinical trial planned to evaluate the targeted agent will focus on patients with relapsed/refractory clear cell sarcoma.

Pathology is the cornerstone of precision medicine, explained Marilyn M. Bui, MD, PhD, who added that, as a whole, the health care specialty needs to step it up in the diagnosis of sarcomas and the differentiation between the various histological subtypes.

The FDA has granted a fast track designation and an orphan drug designation to the orally bioavailable small molecule tubulin-binding agent PTC596 for potential use in patients with leiomyosarcoma; the agent also received a rare pediatric disease designation and an orphan drug designation for potential use in patients with diffuse intrinsic pontine glioma (DIPG).

There is a lot of work that needs to be done to determine the optimal use for immunotherapy in patients with sarcoma.

The FDA has approved ripretinib (Qinlock) for the fourth-line treatment of patients with advanced gastrointestinal stromal tumor (GIST).

The FDA approved pomalidomide (Pomalyst) for the treatment of AIDS-related Kaposi sarcoma, that has become resistant to highly active antiretroviral therapy or for patients with Kaposi sarcoma who are HIV-negative.

Though the use of next-generation sequencing (NGS) may not have immediate clinical implications for patients with sarcoma, it can provide valuable information for data collection and position patients for ongoing clinical trials that have the potential to push the needle forward, explained Gina Z. D'Amato, MD.

Adolescent and young adult patients fall between the 2 age groups that clinicians are used to seeing, leading to gaps in care and poor outcomes.

The FDA has extended the Prescription Drug User Fee Act deadline for a new drug application (NDA) for avapritinib (Ayvakit) as a treatment for adult patients with fourth-line gastrointestinal stromal tumor (GIST). The deadline, which was initially February 14, 2020, has been extended by 3 months to May 14, 2020, according to BluePrint Medicines, the developer of avapritinib.

The presence of the proteins p16 and p21 has shown to be predictive of treatment response in patients with osteosarcoma, a disease that previously had no identified biomarkers to indicate whether or not patients would benefit from therapy, explained C. Parker Gibbs, MD.

The FDA has granted an accelerated approval to tazemetostat (Tazverik) for the treatment of adult and pediatric patients aged ≥16 years old with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection.

The FDA has approved avapritinib (Ayvakit) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

The NDA for Blueprint Medicines' agent avapritinib will be split into two separate submissions for patients with GIST.

Clinical hypnosis offers a non-pharmacological approach to managing chronic pain after cancer treatment.